ABC123 Framework for Urinary Bladder Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Colorado Cancer Center, Aurora, CO
Urinary Bladder Cancer+1 More
ABC123 Framework - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients >60 years old with recently diagnosed advanced, incurable bladder cancer making an initial treatment decision will be enrolled. The team will pilot test the ABC123 framework delivery by an advanced practice provider working with a medical oncologist to inform the overall care planning process. This framework will routinely incorporate and implement existing resources from these 3 transdisciplinary tenets (geriatric, oncology, palliative medicine) into initial care planning in a patient-centered manner. The team will follow patients from initial care planning to 6 months post intervention and assess additional stakeholder feedback on barriers and facilitators to implementation.

Eligible Conditions

  • Urinary Bladder Cancer
  • Bladder Cancer, Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Urinary Bladder Cancer

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 3 years

3 years
Feasibility measured through recruitment
Month 6
Feasibility measured through retention in follow up
baseline to visit 2
Feasibility measured through retention in sessions

Trial Safety

Safety Progress

1 of 3

Other trials for Urinary Bladder Cancer

Trial Design

1 Treatment Group

Older patients with advanced bladder cancer
1 of 1
Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: ABC123 Framework · No Placebo Group · N/A

Older patients with advanced bladder cancer
Behavioral
Experimental Group · 1 Intervention: ABC123 Framework · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
Closest Location: University of Colorado Cancer Center · Aurora, CO
Photo of university of colorado cancer center 1Photo of university of colorado cancer center 2Photo of university of colorado cancer center 3
2004First Recorded Clinical Trial
0 TrialsResearching Urinary Bladder Cancer
248 CompletedClinical Trials

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,554 Previous Clinical Trials
1,910,458 Total Patients Enrolled
American Cancer Society, Inc.OTHER
210 Previous Clinical Trials
98,193 Total Patients Enrolled
Elizabeth KesslerPrincipal InvestigatorUniversity of Colorado, Denver

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are over 65 years old, or over 60 with at least one deficit on a geriatric screen.
You are willing to comply with all study procedures and be available for the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.